GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genmab AS (NAS:GMAB) » Definitions » Cyclically Adjusted PB Ratio

GMAB (Genmab AS) Cyclically Adjusted PB Ratio : 5.42 (As of Dec. 13, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Genmab AS Cyclically Adjusted PB Ratio?

As of today (2024-12-13), Genmab AS's current share price is $20.325. Genmab AS's Cyclically Adjusted Book per Share for the quarter that ended in Sep. 2024 was $3.75. Genmab AS's Cyclically Adjusted PB Ratio for today is 5.42.

The historical rank and industry rank for Genmab AS's Cyclically Adjusted PB Ratio or its related term are showing as below:

GMAB' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 5.82   Med: 22.72   Max: 34.31
Current: 6.16

During the past years, Genmab AS's highest Cyclically Adjusted PB Ratio was 34.31. The lowest was 5.82. And the median was 22.72.

GMAB's Cyclically Adjusted PB Ratio is ranked worse than
81.97% of 599 companies
in the Biotechnology industry
Industry Median: 1.58 vs GMAB: 6.16

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Genmab AS's adjusted book value per share data for the three months ended in Sep. 2024 was $7.481. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $3.75 for the trailing ten years ended in Sep. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Genmab AS Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Genmab AS's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genmab AS Cyclically Adjusted PB Ratio Chart

Genmab AS Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 24.77 29.31 22.44 17.77 10.22

Genmab AS Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.53 10.22 9.25 7.37 6.50

Competitive Comparison of Genmab AS's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Genmab AS's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genmab AS's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genmab AS's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Genmab AS's Cyclically Adjusted PB Ratio falls into.



Genmab AS Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Genmab AS's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=20.325/3.75
=5.42

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genmab AS's Cyclically Adjusted Book per Share for the quarter that ended in Sep. 2024 is calculated as:

For example, Genmab AS's adjusted Book Value per Share data for the three months ended in Sep. 2024 was:

Adj_Book=Book Value per Share/CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=7.481/118.9000*118.9000
=7.481

Current CPI (Sep. 2024) = 118.9000.

Genmab AS Quarterly Data

Book Value per Share CPI Adj_Book
201412 0.591 99.400 0.707
201503 0.646 100.200 0.767
201506 0.710 100.300 0.842
201509 0.771 100.200 0.915
201512 0.855 99.800 1.019
201603 0.881 100.200 1.045
201606 0.946 100.600 1.118
201609 0.985 100.200 1.169
201612 1.136 100.300 1.347
201703 1.187 101.200 1.395
201706 1.347 101.200 1.583
201709 1.433 101.800 1.674
201712 1.633 101.300 1.917
201803 1.765 101.700 2.064
201806 1.756 102.300 2.041
201809 1.806 102.400 2.097
201812 1.993 102.100 2.321
201903 2.001 102.900 2.312
201906 2.037 102.900 2.354
201909 2.841 102.900 3.283
201912 3.219 102.900 3.720
202003 3.272 103.300 3.766
202006 4.141 103.200 4.771
202009 4.478 103.500 5.144
202012 4.780 103.400 5.497
202103 4.919 104.300 5.608
202106 5.000 105.000 5.662
202109 5.150 105.800 5.788
202112 5.132 106.600 5.724
202203 5.118 109.900 5.537
202206 5.288 113.600 5.535
202209 5.387 116.400 5.503
202212 5.943 115.900 6.097
202303 5.996 117.300 6.078
202306 6.410 116.400 6.548
202309 6.817 117.400 6.904
202312 7.079 116.700 7.212
202403 7.272 118.400 7.303
202406 7.038 118.500 7.062
202409 7.481 118.900 7.481

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Genmab AS  (NAS:GMAB) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Genmab AS Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Genmab AS's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Genmab AS Business Description

Industry
Address
Carl Jacobsens Vej 30, Valby, DNK, 2500
Genmab AS is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.